Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant JS001 for resectable non-small cell lung cancer
ChiCTR1900026420Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Major pathological response rate. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900026420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026420.